Ultimovacs
Menu Close ✕
  • About
    • About Ultimovacs
    • Team
    • Board of directors
  • Technology
    • Technology overview
    • Immunotherapy
  • Clinical Studies
    • Phase II trials
    • Phase I trials
    • Partnering
    • Expanded access
  • Investors
    • Shares
    • Financial reports
    • Presentations and publications
    • Investor relations contacts
    • Analyst coverage
    • Governance
    • ESG
    • News
  • Contact
Ultimovacs  –  Investors  –  Analyst coverage

Analyst coverage

  • ABG Sundal Collier Gonzalo Artiach +46 8 566 294 96 gonzalo.castanon@abgsc.se
  • DNB Markets Geir Hiller Holom + 47 977 66 583 geir.hiller.holom@dnb.no
  • Edison Investment Research Soo Romanoff (USA) and Harry Shrives (UK) healthcare@edisongroup.com Click here to receive Edison's research on Ultimovacs in real-time
  • RedEye Equity Research Christian Binder christian.binder@redeye.se
E-mail: mail@ultimovacs.com
E-mail: ir@ultimovacs.com
Phone number: +47 413 80 080
Ullernchausséen 64
0379 Oslo
Norway
View in Google Maps

Technology

  • Technology
  • Clinical studies
  • Immunotherapy

Ultimovacs

  • About Ultimovacs
  • Team
  • Board of directors
  • Contact us

Investors

  • Share information
  • Financial reports
  • Investor relations contacts
  • News
Copyright © Ultimovacs ASA 2023